MXCT:NASDAQ, MaxCyte, Inc.

Why MXCT stock fell on November 10

MaxCyte, Inc. fell 13.1% on Tuesday, November 10, 2026, on 4,482,100 shares, 4.6 times its average daily volume. Headlines around the move:

MXCT stock overview

MaxCyte, Inc. (MXCT:NASDAQ) closed at $1.18 on November 16, 2026, down 0.84% on the day. The stock trades 34.6% below its 52-week high of $1.81 and 83.5% above its 52-week low of $0.643. Over the past year, it lost 31.0%. MaxCyte, Inc. is part of the Consumer Services sector.

Key figures

Price
$1.18
Day change
-0.84%
Volume
1,959,184
Average volume
980,657
Market cap
121M+
52-week range
$0.643 – $1.81
50-day average
$1.25
200-day average
$1.07

Price action over the past year

In 252 trading sessions since November 14, 2025, MXCT closed higher on 111 days (44%). Its best day was October 14, 2026 (+29.67%) and its worst was November 10, 2026 (-13.08%). The stock moved 10% or more in a single session 4 times. It opened at least 5% above the previous day's high 3 times.

Recent signals

MXCT news

About MaxCyte, Inc.

MaxCyte Inc operates in the United States healthcare sector. It develops proprietary electroporation technology, which used blood cells instead of traditional chemical methods to transport medical gene therapies to targeted sites, increasing their safety and efficacy. The company technology finds its use in biotechnology and pharmaceutical firms engaged in cell therapy, including gene editing and immuno-oncology and in drug discovery, development, and biomanufacturing. Its products include MaxCyte STX, VLX, and GT. The company application includes Cell/Gene Therapy, Protein Production, Cell-based Assays, Gene Editing, Cell Line Development, and Viral Vectors/Vaccines. It acquires its income principally from the sale or lease of instruments and processing assemblies.

Similar stocks

Find more stocks like MXCT with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.